DOC defends WellPath contract and announces expanded substance-treatment pilot at Northwest and CRCF
Loading...
Summary
DOC officials told the committee the WellPath contract (cited in testimony as about $44,000,000) covers broad medical services inside facilities and funds enhanced substance-use treatment pilots at CRCF and Northwest; DOC said the Burlington label in budget documents is misleading and that the pilot aims to scale statewide.
Finance leadership and the interim commissioner described the scope and costs of DOC’s contract with WellPath and a substance-use enhanced-treatment pilot during the Feb. 26 Institutions Committee hearing. "44,000,000," a committee member said when shown the WellPath budget line; DOC confirmed the magnitude and explained the contract covers medication, MOUD, mental health care and ambulance transport services.
Pilot program details: DOC said the so-called "Burlington project" listed in the budget document is actually a Northwest/CRCF pilot to provide enhanced substance-use treatment that began at CRCF and Northwest and is being scaled; DOC said the budget reflects $1,200,000 allocated to that pilot from a larger contract line. DOC emphasized the service is not limited to people referred by the accountability court and that the aim is to make the services available as screening and capacity expand.
Relationship with MOUD and medical necessity: DOC and committee members clarified the enhanced treatment is separate from the state's MOUD program; individuals could receive both services. DOC said medical necessity determinations are appropriate and that some questions about statutory definition of "medically necessary" may require further review. "This kind of treatment is not merely for those with opioid use disorder," DOC said, adding services can address methamphetamine and other substance disorders as clinically appropriate.
Oversight and costs: Committee members signaled increased scrutiny of WellPath costs. DOC said it maintains contract oversight, a grievance process, and performance metrics to avoid incentives that would reduce appropriate care. DOC also said it has evaluated bringing care in-state (a comprehensive review in 2024) and that the department remains open to renegotiation or alternate providers but believes current services are fair.
Next steps: Committee members indicated they or health-committee colleagues may invite WellPath or DOC medical leads to brief other committees on scope and cost as part of broader appropriations scrutiny.
